
Opinion|Videos|December 22, 2025
Emergence and Evolution of ctDNA Assays for MRD in TNBC
Author(s)Marija Balic, MD
Emergence and Evolution of ctDNA Assays for MRD in TNBC
Advertisement
Marija Balic, MD, discusses how circulating tumor DNA assays for molecular residual disease detection have evolved in recent years. She details the mechanisms of tumor-informed assays such as Oncodetect, which she used in a subanalysis of the NSABP B-59/GBG-96-GeparDouze trial in triple-negative breast cancer.
Advertisement
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
Lung Cancer News Roundup: June 2026
2
Speed Is the Story: How Sequencing the Human Genome Transformed Cancer Care
3
Zoldonrasib Combos, Including With Daraxonrasib, Yield High Response Rates in PDAC
4
Examining the Strongest Options for Heavily Pretreated Myeloma After Bispecific Therapy
5









































